Transcript Document
The Innovative Medicines Initiative
A winning case for Joint Technology Initiative Status
In our discussion today … 1.
2.
3.
Why Europe needs the Innovative Medicines Initiative About the Innovation Medicines Initiative What we need from you
5 15 Creating new medicines is a high risk journey Medicine Risk assessment analysis Gaining approval 10 Studies in 100-300 patients (Phase II) Studies in healthy volunteers (Phase I) Synthesis of compounds Extensive safety studies Candidate Formulations developed Early safety studies Screening years Idea
It’s time to re-establish our science base – before it’s too late Over the last decade, Europe’s share of the world’s pharmaceutical research and development has steadily decreased 30 25 20 15 10 5 0 Japan Europe USA
Europe is losing it’s scientists
The ‘brain drain’ of researchers away from Europe is increasing 7 out of 10 European-born US doctorate recipients who graduated between 1991 and 2000 had no plans to return to Europe
Source: According to the European Commission 2003 ‘Brain Drain Study’
Health matters to EU citizens too Relative importance of national issues to Europeans % in top 3 responses Job Creation Quality of Health Care Education/schools Inflation/cost of living Anti-terrorism Environmental Protection Social Benefits Crime/law enforcement Narcotics/drug addiction Public Housing Immigration Issues 0 10 20 30 54 40 41 47 50 60 68 68 67 66 72 71 80 77 70 80 90 100
Source : Consensus Research (2004 )
It’s an opportunity to regain EU competitiveness
EU and Member States
Gain competitive advantage for EU, if we act fast
Significant economic value through small and large enterprises More effective healthcare Retain scientific talent and expand science base Public and private biomedical community
Faster drug development process
A framework for academia to work in priority areas and establish collaborations
Vibrant and dynamic scientific environment
And most importantly …
Patients / society
Faster access to innovative therapies such as personalised medicines
More knowledge-based jobs in the EU
More education and training available in the biomedical arena
The population in the EU is ageing rapidly 70 65 60 55 55-64 years 50 45 15-24 years 40 1995 2000 2005 2010 2015 2020 2025
Absolute size in millions for young and old age groups for EU 25, 1995-2030
2030
The elderly consume more healthcare resources
20 15
Spain United Kingdom France Germany Italy
10 5 0 0-4 5-9 10 14 15 19 20 24 25 29 30 34 35 39 40 44 45 49 50 54 55 59 60 64 65 69 70 74 75 79 80 84 85 89 90 94 95+
Age groups
Source: Economic Policy Committee (2001) “Budgetary challenges posed by ageing populations”
New medicines bring value to patients, health care systems and society
Mortality rates in Europe have declined by almost 40% over the last 30 years, thanks in part, to new medicines (EU Health Report) Spending on prescription medicines translates into overall cost savings for healthcare systems and society. When medicines are used to treat an illness, more expensive care – such as surgery and hospital stays – and lost school or work days can often be avoided or decreased
It’s about people living longer, healthier and more productive lives
In our discussion today …
1.
2.
3.
Why Europe needs the Innovative Medicines Initiative About the Innovation Medicines Initiative What we need from you
Science and technology advances present significant opportunities ‘omics Better understanding of disease/drug mechanisms More efficient drug discovery and development Collaborative Research Imaging Better medicines, faster IT Health benefits for EU citizens
It aims to improve the way new medicines are discovered for the benefit of patients Key R&D bottlenecks to overcome: 1.
Safety: Making medicines safer
2.
3.
4.
Efficacy: Making Medicines more effective - O ften disease specific, initial focus on 5 disease areas with high scientific challenges: Cancer; Brain disorders; Inflammatory diseases, Diabetes and Infectious diseases Knowledge Management: Using new technologies to manage and organise data to create knowledge so scientists can predict benefit and risk of new therapies Education and Training: Addressing expertise gaps in Europe
Our approach has already proven to work Pilot project – FP6 – successfully completed
16 Companies – 14 Universities – 7 SMEs from across EU 18 mio euros including European Commission funding Biomarkers in Alzheimer’s Disease:
Better and earlier diagnosis of onset of disease
Predictive Toxicology:
New approaches to measure earlier potential medicine side effects
Recognised and supported by a wide community All Patient Associations consulted are very positive EU Policy Makers Member State policy makers Research based pharmaceutical Industry Patients SMEs Regulators France: INSERM and its academic partners are strongly supportive Physicians / healthcare professionals Academia UK enthusiastically supports the IMI’s priorities and goals Mirror National Initiative are mushrooming in Spain, Nordic countries, Poland, etc
Industry will not be funded by the EC 100% 50% 50% IMI to be funded equally by pharma industry and European Commission Research performed by industry funded by industry 100% Research performed by public organisations funded by EC
IMI - A compelling case for JTI Status
Innovation and development of science base is crucial to Europe Health is high on the political agenda with our ageing population Pharmaceutical innovation brings benefits to people’s health and wealth to society Focused on creating the environment which will enable important new medicines get to patients faster IMI has a clear focus on outcomes, an agreed and proven collaborative approach, and is ready to start implementation Commitment of industry to contribute 100% of own costs
In our discussion today …
1.
2.
3.
Why Europe needs the Innovative Medicines Initiative About the Innovation Medicines Initiative What we need from you
How you can help to create a healthier and more competitive EU
We would like to count on your help in… Spreading the voice about IMI Keeping an eye on 7 th FP calls Creating a strong collaboration between public and private entities Creating biomedical R&D leadership for Europe to benefit patients and society
The ultimate beneficiaries ...
People living longer, healthier and more prosperous lives in the EU
For further information…
http://europa.eu.int/comm/research/imi.html